Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on MiMedx (MDXG) to $10 from $13 and keeps a Buy rating on the shares following recent CMS clarification around provider billing guidelines and the withdrawal of the LCD. This is causing meaningful levels of provider confusion that are likely to weigh on the Wound Care market in Q1, the firm notes. Craig-Hallum says these developments are likely to slow volume momentum in early 2026 compared to prior expectations, prompting a reset to estimates, with Q1 volume growth now modeled at a single-digit percentage sequentially, with expected share taking now more spread out in the model.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MiMedx price target lowered to $10 from $12 at Northland
- MiMedx price target lowered to $10 from $12 at Lake Street
- MiMedx Group Updates Strategy in Wound Care Markets
- MiMedx enters agreement with Regen Lab to distribute RegenKit-WoundGel in U.S.
- MiMedx announces publication in Journal of Inflammation on effects of Purion